Response rate of Hb
Reporting 11 trials of 5 types of HIF-PHIs in 8,167 DD CKD patients[2,
12, 26-30, 33, 40, 41], our network meta-analysis showed significant
increases in Hb response (defined as ΔHb≥1.0 g/dL and Hb level≥11.0
g/dL) in Roxadustat (RR: 1.04, 95% CI: 1.01-1.07, p<0.01,
I2=0%) and Desidustat (RR: 1.22, 95% CI: 1.01-1.48,
p=0.04, I2=0%), compared with ESAs, whereas noticeable reductions were
indicated in Vadadustat (RR: 0.88, 95% CI: 0.82-0.94, p<0.01)
and Molidustat (RR: 0.83, 95% CI: 0.70-0.98, p=0.02,
I2=0%). There was no significant difference between
Daprodustat and ESAs (RR: 0.97, 95% CI: 0.89-1.06, p=0.47,
I2=0%) (Figure 6). The SUCRA net-rankings were
Desidustat (0.99), Roxadustat (0.79), ESAs (0.55), Daprodustat (0.45),
Vadadustat (0.15), and Molidustat (0.07).